https://ymaho.com/enspryng-reduced-the-risk-of-relapses-in-mogad-by-68
Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.